Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
A two-year clinical trial found that Eylea (aflibercept) performed better than Avastin (bevacizumab) in participants with moderate or worse vision loss, while Lucentis (ranibizumab) yielded similar gains. The study confirmed the effectiveness of all three drugs for diabetic macular edema treatment.